Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
View original at finance.yahoo.comMerck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Expects headwind of approximately $2.5 billion from generic competition in 2026
80% confidenceZacks Consensus Estimate for MRK's 2026 sales implies year-over-year increase of 2.59%
80% confidenceKeytruda targets peak sales of $35 billion by 2028
80% confidencePhase III pipeline has almost tripled since 2021
80% confidenceZacks Consensus Estimate for MRK's 2026 EPS suggests decline of 38.75%
80% confidenceExpects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s
80% confidencePositioned to launch around 20 drugs over the next few years, with many having blockbuster potential
80% confidenceZacks Consensus Estimate for BMY's 2026 EPS suggests increase of 0.33%
80% confidenceZacks Consensus Estimate for BMY's 2026 sales implies year-over-year decrease of 2.32%
80% confidenceTargeting $2 billion in annualized cost savings by the end of 2027
80% confidenceOperating expenses expected to decline in 2026, supporting margin expansion
80% confidenceKeytruda will lose patient exclusivity in 2028
80% confidenceAnnual revenue guidance of $46.0-$47.5 billion for 2026
80% confidenceBMY's relatively attractive valuation and more favorable 2026 outlook position it as the more compelling investment choice versus MRK at present
80% confidenceLegacy Portfolio sales expected to decline 12-16% in 2026
80% confidenceAchieved approximately $1 billion in savings in 2025
80% confidence